Valuation: UCB

Market Cap 40.13B 46.35B 37.87B 34.33B 64.43B 4,429B 64.91B 452B 174B 2,253B 174B 170B 7,153B P/E 2026 *
21x
P/E 2027 * 17.4x
Enterprise Value 40.44B 46.71B 38.16B 34.59B 64.92B 4,463B 65.41B 456B 176B 2,270B 175B 172B 7,208B EV / Sales 2026 *
4.65x
EV / Sales 2027 * 3.96x
Free-Float
61.59%
Yield 2026 *
0.69%
Yield 2027 * 0.71%
1 day+1.74%
1 week-1.04%
Current month-2.37%
1 month-4.36%
3 months-23.32%
6 months-17.14%
Current year-11.33%
1 week 200.8
Extreme 200.8
210.93
1 month 200.8
Extreme 200.8
226.2
Current year 200.8
Extreme 200.8
289.5
1 year 191.25
Extreme 191.25
289.5
3 years 65.4
Extreme 65.4
289.5
5 years 65.4
Extreme 65.4
289.5
10 years 54.96
Extreme 54.96
289.5
Manager TitleAgeSince
Chief Executive Officer 67 31/12/2014
Director of Finance/CFO 60 30/06/2020
Chief Tech/Sci/R&D Officer 59 30/04/2024
Director TitleAgeSince
Director/Board Member 55 31/12/2011
Director/Board Member 67 31/12/2014
Director/Board Member 56 23/04/2014
Change 5-day change 1-year change 3-year change Capi.($)
+1.74%-1.04% - - 45.5B
+1.57%-4.11%+41.74%-3.93% 78.04B
+1.89%+0.78%+523.95%+35.09% 57.48B
+2.68%-1.68%-17.44%-36.27% 57.4B
+0.35%-1.87%-11.03%+27.74% 48.81B
+2.38%-0.05%+1.49%+157.52% 45.5B
+0.10%-1.57%+50.05%-15.06% 32.08B
+0.59%-3.60%+47.04%+93.65% 24.62B
+3.53%-5.42%-1.02%+170.53% 20.77B
+2.24%-1.45%+66.12%+103.91% 15.75B
Average +1.49%-3.64%+77.88%+59.24% 42.27B
Weighted average by Cap. +1.39%-3.44%+93.80%+39.82%

Financials

2026 *2027 *
Net sales 8.69B 10.04B 8.2B 7.44B 13.96B 959B 14.06B 97.98B 37.75B 488B 37.69B 36.88B 1,550B 9.68B 11.18B 9.13B 8.28B 15.53B 1,068B 15.65B 109B 42.01B 543B 41.95B 41.04B 1,725B
Net income 1.93B 2.23B 1.82B 1.65B 3.1B 213B 3.12B 21.76B 8.38B 108B 8.37B 8.19B 344B 2.32B 2.68B 2.19B 1.99B 3.73B 257B 3.76B 26.2B 10.09B 130B 10.08B 9.86B 414B
Net Debt 306M 353M 288M 261M 490M 33.71B 494M 3.44B 1.33B 17.15B 1.32B 1.3B 54.45B -1.81B -2.09B -1.71B -1.55B -2.9B -199B -2.92B -20.37B -7.85B -101B -7.84B -7.67B -322B
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
14/09/26 €208.86 +0.23% 32,690
11/09/26 €208.38 +3.16% 58,523
10/09/26 €201.99 -1.90% 14,839
09/09/26 €205.90 -1.19% 20,079
08/09/26 €208.39 -2.00% 28,269
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
210.50EUR
Average target price
285.00EUR
Spread / Average Target
+35.39%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!